ReviewEye (London, England)2012
Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation.
Review in Eye (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Ophthalmological manifestations in autoimmune diseases: Overcoming diagnostic and therapeutic challenges.World journal of experimental medicine · 2025Review
- Comparative Efficacy of Interleukin-7 and -15 Blockade in Alleviating Experimental Chronic Uveitis and Suppressing Pathogenic Memory CD4+ T Cells.Investigative ophthalmology & visual science · 2025Article
- A clearer vision: insights into juvenile idiopathic arthritis-associated uveitis.Proceedings (Baylor University. Medical Center) · 2024Article
- Involvement of the systemic microcirculation in pediatric uveitis.Pediatric rheumatology online journal · 2023Article
- Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review.Children (Basel, Switzerland) · 2023Review
- Association Between Atherosclerosis-Related Cardiovascular Disease and Uveitis: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- A Network of Serum Proteins Predict the Need for Systemic Immunomodulatory Therapy at Diagnosis in Noninfectious Uveitis.Ophthalmology science · 2022Article
- SARS-CoV-2 vaccination and uveitis: Are they linked?Annals of medicine and surgery (2012) · 2022Review
- Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.Ophthalmology and therapy · 2022Article
- Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis.Acta ophthalmologica · 2022Article
- Regulatory T Cells: Therapeutic Opportunities in Uveitis.Frontiers in ophthalmology · 2022Review
- Intravitreal Dexamethasone Implants for Refractory Macular Edema in Eyes with Noninfectious Uveitis.Journal of clinical medicine · 2021Article
- Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.Annals of eye science · 2021Article
- Intravitreal Dexamethasone Implant in the Treatment of Non-infectious UveitisTurkish journal of ophthalmology · 2019Article
- Immune Privilege and Eye-Derived T-Regulatory Cells.Journal of immunology research · 2018Review
- Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.Clinical and experimental medicine · 2016Review
- Juvenile idiopathic arthritis-associated uveitis.Pediatric rheumatology online journal · 2016Review
- 2-Methoxyestradiol Alleviates Experimental Autoimmune Uveitis by Inhibiting Lymphocytes Proliferation and T Cell Differentiation.BioMed research international · 2016Article
- Investigation of the relationship between the onset of arthritis and uveitis in genetically predisposed SKG mice.Arthritis research & therapy · 2015Article
- Uveitis associated with juvenile idiopathic arthritis.Nature reviews. Rheumatology · 2015Review
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blockbuster drug paradigm is under increasing scrutiny across the biopharmaceutical industry. Intraocular inflammation poses particular challenges to this, given the heterogeneity of conditions in the uveitis spectrum, and the increasing acknowledgement of individual patient and disease variance in underlying immune responses. This need has triggered a drive towards personalised and stratified medicine, supported and enabled as a result of continued development of both experimental models and molecular biological techniques and improved clinical classification. As such we have the ability now to systematically appraise at a genomic, transcriptomic, and proteomic level individual immunophenotype, and the promise that in the eye this can be augmented by in vivo immune imaging to identify individual immunopathology. With such advances all running in parallel, we are entering an era of experimental medicine that will facilitate early diagnosis, generate biomarkers for accurate prognostication, and enable the development of individualised and targeted therapies, which can progress rapidly into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.